Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model (transgenic mice)
PubMed 33831349 · doi:10.1016/j.neuron.2021.03.024
What was done
Researchers generated transgenic mice combining human mutant tau (P301S), inducible astrocyte-specific Cre recombinase (Aldh1l1-CreERT2), and floxed human APOE3 or APOE4 alleles. At 5.5 months of age (after tau pathology had developed), mice received tamoxifen or vehicle to conditionally delete astrocytic apoE. Brains were evaluated at 9.5 months of age for phosphorylated tau (pTau) pathology, neurodegeneration, synaptic loss, microglial phagocytosis of synaptic elements, and single-nucleus RNA sequencing across brain cell populations.
What was found
The abstract reports no exact numbers, percentages, or statistical values. Removing astrocytic APOE4 decreased pTau pathology, reduced tau-mediated neurodegeneration, and prevented tau-induced synaptic loss. Single-nucleus RNA sequencing showed reduced disease-associated gene signatures across neurons, oligodendrocytes, astrocytes, and microglia. Astrocytic APOE4 deletion also decreased microglial phagocytosis of synaptic elements.
Why it matters
This paper demonstrates that astrocyte-derived apoE4 actively drives tau pathology and microglial synaptic pruning, indicating that cell-specific reduction of astrocytic APOE4 may be therapeutic even after tauopathy onset.
Limits
The study was conducted exclusively in a transgenic mouse model using a non-Alzheimer mutant tau variant (P301S), limiting direct translation to human sporadic Alzheimer's disease. The abstract provides no sample sizes, effect sizes, or variance metrics. Feasibility of selective astrocytic APOE4 targeting in humans was not tested.
Cited by
- supports Astrocytes are the primary source of APOE production in the brain.